ADXN — Addex Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.42m
- $2.58m
- CH₣0.17m
Brief: Addex Therapeutics Collaborates With CMTA To Advance Gaba B Pam As Treatment For CMT1a
Brief: Addex H1 Net Loss At CHF 7.3 Million
Brief: Addex Therapeutics And Indivior Extend Research Collaboration On Gabab Positive Allosteric Modulators
Brief: Addex Establishes At-The-Market ADS Equity Sale Program
Brief: Addex Therapeutics Starts Phase 2B/3 Study With Dipraglurant For Dyskinesia
Brief: Addex Starts Phase 2 Clinical Study Of ADX71149 For Epilepsy
Brief: Addex Says Dipraglurant Restores Synaptic Plasticity In Two Models Of Dystonia
Brief: Addex Therapeutics Q1 Net Loss At CHF -2.6 Million
Swiss stocks - Factors to watch on April 8
Brief: Addex Therapeutics Files For Stock Shelf Of Up To $150 Mln
Brief: Addex Therapeutics FY Net Loss narrows to CHF 12.9 Mln
Brief: Addex Therapeutics Extends Collaboration With Prominent Swiss Biotech
Brief: Addex Therapeutics Completes 2020 With Cash Position Of CHF 18.7 Mln
U.S. STOCKS ON THE MOVE-CVS Health, AutoNation, Cortexyme, Socket Mobile
U.S. STOCKS ON THE MOVE-Kala, Carnival Corp, CrowdStrike, Diffusion
U.S. STOCKS ON THE MOVE-Socket Mobile, bluebird bio, AMC Entertainment, Southwest Airlines
U.S. STOCKS ON THE MOVE-U.S.-listed miners, Exxon Mobil, Blackberry, Palantir
Addex Therapeutics: Rises as alcohol disorder drug promising in review
Brief: Addex Gabab Positive Allosteric Modulator Demonstrates Promise In Alcohol Use Disorder